HAART : Current & Future
5 Dec, 3:30 PM
From the early days of antiretroviral (ARV) monotherapy, to the mid 1990’s when triple therapy (HAART) was discovered to be not only more effective but less toxic, there has been ongoing work to change the face of HIV treatment. Standard of care for HIV treatment requires the combination of NRTI, NNRTI, protease inhibitors, and integrase strand transfer inhibitors. The current challenges with antiretroviral therapy (ART) are pill burden, toxicity and drug-resistance. Newer NRTIs such as abacavir, tenofovir, lamivudine and emtricitabine are now associated with lesser occurrence of mitochondrial toxicity. The landscape of ART is constantly changing and to equip us with all the latest updates, Dr. N Kumarasamy joins us LIVE on Medflix!
Medflix is a new platform by PlexusMD, India's most active and trusted doctor community. On Medflix, you can discover live surgeries, discussions, conferences and courses from some of the top doctors and institutions across the world. Join clubs in your areas of interest and access hundreds of amazing live discussions everyday.